Treatment of severe sepsis and septic shock: The future has begin;Tratamiento de la sepsis grave y el shock séptico: El futuro ha empezado

Medicina Intensiva

Volumn 25, Issue 2, 2001, Pages 62-65

  Torrabadella De Reynoso, Pablo ^a   Salgado Remigio, Antonio ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; SEPSIS; SEPTIC SHOCK; TREATMENT PLANNING;

EID: 0035090955     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5691(01)79653-2     Document Type: Editorial

References (38)

1. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: A common clinical sequence
2. Sepsis. Lessons learned in the last century and future directions
3. Trends in infectious diseases mortality in the United States
4. Pathogenetic mechanisms of septic shock
5. Sepsis: Asignatura pendiente para el siglo XXI
6. Septic shock
7. L-arginine: Nitric oxide pathway in endotoxinemia and human septic shock
8. Anti-inflammatory cytokine profile and mortality in febrile patients
9. Interleukin-10 and he monocyte macrophage induced inflammatory response in septic shock
10. Sepsis: A new hypothesis for pathogenesis of the disease process
11. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
12. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study
13. Suspensión cautelar del anticuerpo monoclonal antiendotoxina HA-1A
14. Óxido nítrico y sus inhibidores en la sepsis y el shock séptico
15. El tratamiento de la sepsis grave y el shock séptico. Aprendiendo de los fracasos
16. Search for effective immunomodulating strategies against sepsis
17. Treatment of severe sepsis in patients with highly IL-6 levels with anti-TNF monoclonal antibody-fragment Afelimomab (MAK 195F): The RAMSES Study
18. Randomized placebo-controlled trial of the anti-TNF antibody fragment Afelimomab in the hyperinflammatory response in severe sepsis. The RAMSES Study
19. The anti-inflammatory properties of antithrombin III: New therapeutic implications
20. Inflammatory mediators and their influence on heamostasis
21. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
22. Protein C in the treatment of coagulopathy in meningococcal disease
23. Antitrombina en el paciente crítico
24. Antithrombin III in patients with severe sepsis, A randomized, placebo-controlled, double-blind multicentre trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
25. Antithrombin III in patients with severe sepsis, A randomized, placebo-controlled, double-blind multicentre trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
26. Antithrombin III replacement therapy in patients with sepsis and/or postsurgical complications: A controlled, randomized multicenter study
27. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
28. Activación de la vía extrínseca de la coagulación en el shock séptico
29. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
30. Nuevos tratamientos de la sepsis grave. Una encrucijada científica, económica y ética
31. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
32. Immunotherapy of severe sepsis and septic shock: Is there a future?
33. Do we really know the epidemiology and clinical course of sepsis?
34. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units
35. Nosocomial bacteremia in critically ill patients: A multicenter study evaluating epidemiology and prognosis
36. Análisis coste-eficacia del tratamiento con anticuerpos monoclonales antiendotoxina en la sepsis por gramnegativos
37. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis: Economic assessment of a new therapeutic agent
38. Cost-effectivenes of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients